ICON Public Limited Company
ICLRHealthcareNASDAQDiagnostics & Research · Last scanned Jul 15, 2026
Scan Results
Daily timeframeICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. Valued at $13.28B, ICLR is a large-cap name in its sector. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Market Cap
$13.28B
Beta
1.22
P/E (TTM)
75.81
P/E (Fwd)
14.50
EPS (TTM)
$2.27
EPS (Fwd)
$11.87
ROE
1.8%
ROA
3.5%
Cash
$765.2M
Total Debt
$3.54B
Free CF
$809.3M
52W Change
19.5%
Annual Financials
Cash vs Debt
The company holds $765.2M in cash, though total debt stands at $3.54B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $809.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 1.8% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $7.74B (2022) to $8.25B (2025).
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing ICLR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.